In this rapid-response format, expert faculty examine key abstracts from the Neuroscience Education Institute (NEI) Congress, focusing on muscarinic agents such as xanomeline-trospium and emraclidine, which show potential in targeting schizophrenia s cognitive and negative symptom domains. Through expert-led discussions on mechanisms, efficacy, and emerging evidence, participants will explore how these agents fit into conventional treatment paradigms, equipping them with knowledge to make informed decisions on the adoption of muscarinic agents in clinical practice.
- Provider:Vindico Medical Education, LLC
- Activity Link: https://www.healio.com/cme/psychiatry/20241115/breakthroughs-in-schizophrenia-treatment-with-muscarinic-agents
- Start Date: 2024-11-17 06:00:00
- End Date: 2024-11-17 06:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: Bristol Myers Squibb - Amount: 128195.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest